

as arrears of land revenue from the company. Meanwhile, M/s. Tridoss Labs Ltd. have filed a Writ petition in the Bombay High Court on 16th April, 2001 against the show-cause notice of National Pharmaceutical Pricing Authority.

Sale of medicines without price approval by M/s. Hoechst

4606. SHRI VIJAY SINGH YADAV: Will the Minister of CHEMICALS AND FERTILIZERS be pleased to state:

(a) whether it is a fact the M/s Hoechst are selling Avil, Proctosedyl and Sofradex without price approval;

(b) if so, what are the details thereof;

(c) what is the overcharged amounts, product-wise; and

(d) what action has been taken by Government to recover the amount?

THE MINISTER OF CHEMICALS AND FERTILIZERS (SHRI SUKHDEV SINGH DHINDSA): (a) to (d) Avil, Proctosedyl and Sofradex are medicines based on scheduled bulk drugs under the Drugs (Price Control) Order, 1995 for which non-ceiling prices were approved to M/s. Roussel (I) Ltd. The company was renamed as M/s. Hoechst Marion Roussel Ltd. (HMR). As per the price lists submitted by M/s. HMR from time to time, the company has been following the prices fixed by the Government. However, in the price list submitted by the company on 18.01.2000 (effective from 01.01.2000) the names of Avil Injections, Sofradex F Cream, Sofradex Cream and Protosedyl Ointment do not appear. It has come to the notice of the National Pharmaceutical Pricing Authority (NPPA) that these products have been manufactured by M/s. HUB Pharmaceuticals Ltd. Pune. That company has claimed that being an SSI, it is exempted from the non-ceiling prices under DPCO's 95. There are no ceiling prices for these packs. However, these products are shown as that of M/s. Hoechst Roussel in various medical journals like ORG-MARG (February, 2001) Drugs Today, the Indian Drug Review (IDR) and the MIMS. National Pharmaceutical Pricing Authority has served notices to M/s. HMR under DPCO '95